151 related articles for article (PubMed ID: 34482695)
21. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
[TBL] [Abstract][Full Text] [Related]
22. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
McKnight BN; Kim S; Boerner JL; Viola NT
Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
[TBL] [Abstract][Full Text] [Related]
23.
Liu H; Sun H; Zhang B; Liu S; Deng S; Weng Z; Zuo B; Yang J; He Y
Breast Cancer; 2020 May; 27(3):372-380. PubMed ID: 31781983
[TBL] [Abstract][Full Text] [Related]
24.
Gao F; Peng C; Zhuang R; Guo Z; Liu H; Huang L; Li H; Xu D; Wen X; Fang J; Zhang X
Nucl Med Biol; 2019; 72-73():62-69. PubMed ID: 31330414
[TBL] [Abstract][Full Text] [Related]
25. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.
Xu Q; Ge Q; Zhou Y; Yang B; Yang Q; Jiang S; Jiang R; Ai Z; Zhang Z; Teng Y
EBioMedicine; 2020 Jan; 51():102609. PubMed ID: 31915116
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer.
Ramos N; Baquero-Buitrago J; Ben Youss Gironda Z; Wadghiri YZ; Reiner T; Boada FE; Carlucci G
J Nucl Med; 2020 Mar; 61(3):437-442. PubMed ID: 31481582
[TBL] [Abstract][Full Text] [Related]
27. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
28. Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer.
Das A; Prajapati A; Karna A; Sharma HK; Uppal S; Lather V; Pandita D; Agarwal P
Chem Biol Interact; 2023 May; 376():110443. PubMed ID: 36893906
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma.
Cigliano A; Pilo MG; Mela M; Ribback S; Dombrowski F; Pes GM; Cossu A; Evert M; Calvisi DF; Utpatel K
Medicina (Kaunas); 2019 Dec; 56(1):. PubMed ID: 31861475
[No Abstract] [Full Text] [Related]
30. Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer.
Wang J; Wang Y; Shen F; Xu Y; Zhang Y; Zou X; Zhou J; Chen Y
Cancer Med; 2018 Nov; 7(11):5665-5678. PubMed ID: 30334367
[TBL] [Abstract][Full Text] [Related]
31. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
32. Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma.
Kiseljak-Vassiliades K; Zhang Y; Kar A; Razzaghi R; Xu M; Gowan K; Raeburn CD; Albuja-Cruz M; Jones KL; Somerset H; Fishbein L; Leong S; Wierman ME
Endocrinology; 2018 Jul; 159(7):2532-2544. PubMed ID: 29790920
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.
Chen S; Zhou Q; Guo Z; Wang Y; Wang L; Liu X; Lu M; Ju L; Xiao Y; Wang X
J Cell Mol Med; 2020 Jan; 24(2):1804-1821. PubMed ID: 31821699
[TBL] [Abstract][Full Text] [Related]
34. Enigmatic MELK: The controversy surrounding its complex role in cancer.
McDonald IM; Graves LM
J Biol Chem; 2020 Jun; 295(24):8195-8203. PubMed ID: 32350113
[TBL] [Abstract][Full Text] [Related]
35. MELK is not necessary for the proliferation of basal-like breast cancer cells.
Huang HT; Seo HS; Zhang T; Wang Y; Jiang B; Li Q; Buckley DL; Nabet B; Roberts JM; Paulk J; Dastjerdi S; Winter GE; McLauchlan H; Moran J; Bradner JE; Eck MJ; Dhe-Paganon S; Zhao JJ; Gray NS
Elife; 2017 Sep; 6():. PubMed ID: 28926338
[TBL] [Abstract][Full Text] [Related]
36. Development of [
Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372
[TBL] [Abstract][Full Text] [Related]
37. MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.
Li G; Yang M; Zuo L; Wang MX
Oncol Lett; 2018 Jun; 15(6):9934-9940. PubMed ID: 29805690
[TBL] [Abstract][Full Text] [Related]
38. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
[TBL] [Abstract][Full Text] [Related]
39. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.
Pitner MK; Taliaferro JM; Dalby KN; Bartholomeusz C
Expert Opin Ther Targets; 2017 Sep; 21(9):849-859. PubMed ID: 28764577
[TBL] [Abstract][Full Text] [Related]
40. Maternal embryonic leucine zipper kinase in tumor cells and tumor microenvironment: An emerging player and promising therapeutic opportunity.
Tang BF; Yan RC; Wang SW; Zeng ZC; Du SS
Cancer Lett; 2023 Apr; 560():216126. PubMed ID: 36933780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
